OverviewSuggest Edit

Orphazyme develops therapies for the treatment of a family of serious genetic disorders called lysosomal storage diseases. The Company focuses on development of cell-protective properties of the heat shock response, a natural defense mechanism in various cells; and arimoclomol, an investigative medicinal product that regulates the production of other proteins in the cell. 

TypePublic
Founded2009
HQKøbenhavn, DK
Websiteorphazyme.com

Latest Updates

Employees (est.) (Jul 2021)141
Revenue (FY, 2020)KR0
Share Price (Sept 2021)KR30.1
Cybersecurity ratingAMore

Key People/Management at Orphazyme

Thomas Kirkegaard Jensen

Thomas Kirkegaard Jensen

Chief Scientific Officer, Co-Founder
Molly Painter

Molly Painter

Orphazyme US President
Christophe Bourdon

Christophe Bourdon

Chief Executive Officer
Anders Vadsholt

Anders Vadsholt

Chief Financial Officer
Thomas Blaettler

Thomas Blaettler

Chief Medical Officer
Terri Stevens

Terri Stevens

Chief Business Officer
Show more

Orphazyme Office Locations

Orphazyme has offices in København, Chicago and Newton
København, DK (HQ)
Ole Maaløes Vej 3
Chicago, IL, US
180 N LaSalle St #3475
Newton, MA, US
Riverside Center, 275 Grove St #2, Auburndale
Show all (3)

Orphazyme Financials and Metrics

Orphazyme Revenue

DKK

Net income (FY, 2020)

(633.2m)

EBIT (FY, 2020)

(608.5m)

Market capitalization (14-Sept-2021)

1.1b

Closing stock price (14-Sept-2021)

30.1

Cash (31-Dec-2020)

726.9m
Orphazyme's current market capitalization is kr1.1 b.
Annual
DKKFY, 2018FY, 2019FY, 2020

Revenue

General and administrative expense

35.1m50.5m247.3m

R&D expense

196.5m285.4m361.3m

Operating expense total

231.7m336.0m608.5m
Half Year
DKKH1, 2019H1, 2020

General and administrative expense

23.3m78.6m

R&D expense

141.7m167.0m

Operating expense total

165.1m245.6m

EBIT

(165.1m)(245.6m)
Annual
DKKFY, 2018FY, 2019FY, 2020

Cash

394.7m123.6m726.9m

Prepaid Expenses

14.2m13.4m

Current Assets

423.4m148.2m783.7m

PP&E

1.9m3.7m4.7m
Half Year
DKKH1, 2020

Cash

610.4m

Current Assets

638.2m

PP&E

4.2m

Total Assets

676.4m
Annual
DKKFY, 2018FY, 2019FY, 2020

Depreciation and Amortization

1.4k3.8k

Accounts Payable

5.9k(2.8k)

Cash From Operating Activities

(234.8k)(326.8k)(539.1m)

Purchases of PP&E

(743.0)(2.8k)
Half Year
DKKH1, 2019H1, 2020

Depreciation and Amortization

2.1k2.3k

Accounts Payable

(11.4k)37.4k

Cash From Operating Activities

(166.6k)(204.2k)

Purchases of PP&E

(1.1k)(1.2k)
DKKFY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Orphazyme Acquisitions / Subsidiaries

Company NameDateDeal Size
Orphazyme Schweiz GmbH
Orphazyme US, Inc

Orphazyme Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Orphazyme Online and Social Media Presence

Embed Graph

Orphazyme News and Updates

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Orphazyme A/S and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, Sept. 7, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Orphazyme A/S ("Orphazyme" or "the Company") (NASDAQ: ORPH) for violations of the federal securities laws. Investors who...

Orphazyme reports business highlights and financial results in Interim Report First Half 2021

Orphazyme A/SCompany announcementNo. 21/2021CVR No.: 32266355

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Orphazyme A/S Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ORPH

NEW YORK, Aug. 29, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/or traceable to Orphazyme's September 29, 2020 initial public offering (the "IPO" or "Offering"); and/or...

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orphazyme, CorMedix, Koninklijke Philips, and Sesen Bio and Encourages Investors to Contact the Firm

NEW YORK, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Orphazyme A/S (NASDAQ: ORPH), CorMedix Inc. (NASDAQ: CRMD), Koninklijke Philips N.…

Orphazyme to host Interim Report First Half 2021 investor call on August 31, 2021

Orphazyme A/SInvestor news        No. 08/2021Company Registration No. 32266355

ORPH BREAKING ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Orphazyme A/S Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ORPH

NEW YORK, Aug. 24, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/or traceable to Orphazyme’s September 29, 2020 initial public offering (the “IPO” or “Offering”); and/or (2) be…
Show more

Orphazyme Blogs

New publication date for Orphazyme’s Interim Report H1 2021

New publication date for Orphazyme’s Interim Report H1 2021 Content Import Thu, 08/05/2021 - 12:12 New publication date for Orphazyme’s Interim Report H1 2021 August 5, 2021 at 12:12 PM EDT This release is a backfill from a News Wire News…

Orphazyme to present at upcoming investor conferences

Orphazyme A/S Investor news          No. 05/2021 Company Registration No. 32266355 Copenhagen, Denmark and Chicago, IL , USA, April 27 , 202 1 – Orphazyme A/S [ORPHA.CO (DK); ORPH (US)], a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of

Orphazyme Frequently Asked Questions

  • When was Orphazyme founded?

    Orphazyme was founded in 2009.

  • Who are Orphazyme key executives?

    Orphazyme's key executives are Thomas Kirkegaard Jensen, Molly Painter and Christophe Bourdon.

  • How many employees does Orphazyme have?

    Orphazyme has 141 employees.

  • Who are Orphazyme competitors?

    Competitors of Orphazyme include Pharming Group, Aruvant and Microbiotix.

  • Where is Orphazyme headquarters?

    Orphazyme headquarters is located at Ole Maaløes Vej 3, København.

  • Where are Orphazyme offices?

    Orphazyme has offices in København, Chicago and Newton.

  • How many offices does Orphazyme have?

    Orphazyme has 3 offices.